PCSK9 and breast cancer: Genetic variants of PCSK9 that increase LDL levels were associated with a higher risk of breast cancer, while LDL-lowering variants, resembling the effects of PCSK9 inhibitors, showed a significant correlation with a reduced risk of developing breast cancer [13].